EBR Systems (ASX:EBR) will meet with the US Food and Drug Administration on Dec. 20 to discuss the pre-market approval application for its wireless cardiac pacing device using its WiSE CRT system, according to a Friday filing with the Australian bourse.
The so-called Day-100 meeting will allow both parties to discuss the status of the company's application and see if the regulator needs any additional requirements to advance the review, the filing said.
The meeting was made possible via the device's breakthrough device designation, which allows interactive communication during the evaluation process, the filing added.
The company's shares jumped nearly 5% in recent Friday trade.
Price (AUD): $0.93, Change: $+0.04, Percent Change: +4.85%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。